- Biocept Inc BIOC has collaborated with Quest Diagnostics Inc DGX to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel.
- The Biocept Target Selector NGS-based liquid biopsy assay is a less invasive, lab-developed test used for genomic profiling in patients with advanced non-small-cell lung cancer to help qualify them for advanced targeted therapies and monitor the effectiveness of treatment.
- The two parties expect the service to be available to Quest Diagnostics' providers and patients in the fourth quarter of 2021.
- Price Action: BIOC shares are up 4.52% at $4.39 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
